Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Tax Provisions (2020 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Tax Provisions for 8 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 105.83% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.9 million through Dec 2025, up 1322.04% year-over-year, with the annual reading at $46.0 million for FY2025, 1332.25% up from the prior year.
  • Tax Provisions hit $2.7 million in Q4 2025 for Ironwood Pharmaceuticals, down from $27.9 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $32.1 million in Q4 2023 to a low of -$336.9 million in Q2 2021.
  • Historically, Tax Provisions has averaged -$9.5 million across 5 years, with a median of $13.5 million in 2023.
  • Biggest YoY gain for Tax Provisions was 4325.0% in 2022; the steepest drop was 964.94% in 2022.
  • Year by year, Tax Provisions stood at $4.9 million in 2021, then plummeted by 964.94% to -$42.4 million in 2022, then skyrocketed by 175.74% to $32.1 million in 2023, then tumbled by 244.27% to -$46.3 million in 2024, then surged by 105.83% to $2.7 million in 2025.
  • Business Quant data shows Tax Provisions for IRWD at $2.7 million in Q4 2025, $27.9 million in Q3 2025, and $14.2 million in Q2 2025.